BridgeBio Pharma (BBIO) Gains from Sales and Divestitures (2017 - 2025)

BridgeBio Pharma has disclosed Gains from Sales and Divestitures across 9 years of filings, most recently posting $1.9 million for Q2 2025.

• Gains from Sales and Divestitures for Q2 2025 came in at $1.9 million, up 2170.85% year-over-year; the trailing twelve-month figure through Jun 2025 was $1.9 million (up 2170.85% YoY), and the FY2024 annual result was $85453.0, down 59.67% from the prior year.
• Gains from Sales and Divestitures came in at $1.9 million for Q2 2025 at BridgeBio Pharma, up from $879051.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.9 million in Q3 2024 to a low of $85453.0 in Q1 2024.
• The 5-year median for Gains from Sales and Divestitures is $359456.0 (2021), against an average of $716680.2.
• Across the five-year window, Gains from Sales and Divestitures soared 22364.55% in 2021 and slumped 89.16% in 2023, its largest moves.
• BridgeBio Pharma's Gains from Sales and Divestitures stood at $395672.0 in 2021, then soared by 393.79% to $2.0 million in 2022, then plunged by 89.16% to $211860.0 in 2023, then sank by 59.67% to $85453.0 in 2024, then jumped by 2170.85% to $1.9 million in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.9 million (Q2 2025), $879051.0 (Q1 2025), and $85453.0 (Q4 2024), per Business Quant data.